IndieBio

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

MAA'VA is focused on creating next-generation green building materials that serve as functional alternatives to traditional concrete. The company incorporates recycled plastics, carbon sequestration techniques, and the upcycling of manufacturing waste into its products. By addressing critical issues such as the shortage of river sand, water scarcity, climate change, and waste management, MAA'VA aims to promote sustainable construction practices. Its materials are designed for use in both conventional construction and 3D printing applications, thereby enabling clients to adopt eco-friendly options for their building needs.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

MAA'VA is focused on creating next-generation green building materials that serve as functional alternatives to traditional concrete. The company incorporates recycled plastics, carbon sequestration techniques, and the upcycling of manufacturing waste into its products. By addressing critical issues such as the shortage of river sand, water scarcity, climate change, and waste management, MAA'VA aims to promote sustainable construction practices. Its materials are designed for use in both conventional construction and 3D printing applications, thereby enabling clients to adopt eco-friendly options for their building needs.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

JointechLabs develops point-of-care regenerative medicine devices that enable access to cell-based therapies in doctors' offices, hospitals, and clinics. Its closed-loop, disposable systems process human tissue to produce autologous fat grafts and fat-derived stem cells, simplifying personalized cell- and tissue-based treatments for orthopedic and aesthetic procedures. Core products include a system for processing adipose tissue and related kits designed for use at the point of care, with regional variants for the United States and international markets. The company aims to extend applications through a pipeline that covers biologic drugs and 3D bioprinted products to support orthopedic, wound healing, and plastic and reconstructive surgery. By focusing on safe, time-efficient workflows, JointechLabs seeks to reduce costs and improve accessibility to regenerative therapies in clinical settings.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

JointechLabs develops point-of-care regenerative medicine devices that enable access to cell-based therapies in doctors' offices, hospitals, and clinics. Its closed-loop, disposable systems process human tissue to produce autologous fat grafts and fat-derived stem cells, simplifying personalized cell- and tissue-based treatments for orthopedic and aesthetic procedures. Core products include a system for processing adipose tissue and related kits designed for use at the point of care, with regional variants for the United States and international markets. The company aims to extend applications through a pipeline that covers biologic drugs and 3D bioprinted products to support orthopedic, wound healing, and plastic and reconstructive surgery. By focusing on safe, time-efficient workflows, JointechLabs seeks to reduce costs and improve accessibility to regenerative therapies in clinical settings.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Pembient, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in producing synthetic rhino horn and elephant ivory using advanced biotechnological methods, including DNA manipulation and 3D printing of keratin. By offering these bio-fabricated products at prices lower than those that drive poaching, Pembient aims to combat the illegal wildlife trade, which is estimated to be a $20 billion black market. The company also manufactures carvable horns for creating durable goods such as jewelry, libation cups, and chopsticks. Through its innovative approach, Pembient seeks to replace the demand for illegal wildlife products with sustainable alternatives, thereby contributing to the conservation of endangered species.